BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
BioNTech (Nasdaq: BNTX) will report first quarter 2026 financial results on May 5, 2026 and host a conference call and webcast at 8:00 a.m. ET / 2:00 p.m. CET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioNTech (Nasdaq: BNTX) will report first quarter 2026 financial results on May 5, 2026 and host a conference call and webcast at 8:00 a.m. ET / 2:00 p.m. CET.
Investors should register in advance to receive dial‑in numbers and a PIN; slides and audio will be available on the company website and a replay will be archived for 30 days.
Details
News Market Reaction – BNTX
On Apr 21, the day this news came out, BNTX closed 6.09% above the previous close.
Data tracked by StockTitan Argus for the Apr 21 session.
Key Figures
- Quarter reported
- First quarter 2026
- Period for upcoming financial results
- Earnings date
- May 5, 2026
- Scheduled Q1 2026 results announcement
- Conference call time (ET)
- 8:00 a.m. ET
- Start time of earnings call
- Conference call time (CET)
- 2:00 p.m. CET
- Start time of earnings call
- Webcast archive period
- 30 days
- Duration replay will be available
Previous Earnings date Reports
-
Announced timing and access details for Q4 and FY 2025 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.